Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
抗 PD-1 抗体单药治疗与抗 PD-1 抗体联合抗 CTLA-4 抗体联合治疗作为不可切除或转移性黏膜黑色素瘤的一线免疫疗法：一项回顾性多中心研究，纳入 329 例日本病例（JMAC 研究）
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100325
Nakamura, Y; Namikawa, K; Yoshikawa, S; Kiniwa, Y; Maekawa, T; Yamasaki, O; Isei, T; Matsushita, S; Nomura, M; Nakai, Y; Fukushima, S; Saito, S; Takenouchi, T; Tanaka, R; Kato, H; Otsuka, A; Matsuya, T; Baba, N; Nagase, K; Inozume, T; Fujimoto, N; Kuwatsuka, Y; Onishi, M; Kaneko, T; Onuma, T; Umeda, Y; Ogata, D; Takahashi, A; Otsuka, M; Teramoto, Y; Yamazaki, N
